Ok, I would love to know how regulatory bodies rate evidence from this type of study, compared to a placebo controlled study?
If we see any effects in the intervention part of this study, how can we be confident that effects are due to the drug or due to the placebo effect?
Do Dr T and the team not expect placebo effects to extend to cardiotoxicity outcomes??
Ann: Ethics submission to commence cardioprotection trial, page-24
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |